With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

Eli Lilly pre-announced the following drug numbers for Q4: Mounjaro — $3.5 billion, up from $3.1 billion in Q3 Zepbound — $1.9 billion, up from $1.26 billion in Q3. The biopharma reported ...

Similar to third-quarter 2024, management stated that sales of both Mounjaro and Zepbound were hurt by lower-than-expected channel inventory of the products. Eli Lilly is scheduled to report ...

Shares of Eli Lilly have been falling in recent months ... including its top GLP-1 drugs, Mounjaro ($3.1 billion) and Zepbound ($1.3 billion). Late last year, regulators approved Zepbound as ...

Eli Lilly shares could remain under the microscope ... While the drugmaker said it anticipates sales of its flagship weight-loss drugs Mounjaro and Zepbound to accelerate as it ramps up production ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...